{"name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","slug":"arbeitsgemeinschaft-medikamentoese-tumortherapie","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Cetuximab Induction","genericName":"Cetuximab Induction","slug":"cetuximab-induction","indication":"Colorectal cancer","status":"phase_2"},{"name":"Cetuximab Radioimmunotherapy","genericName":"Cetuximab Radioimmunotherapy","slug":"cetuximab-radioimmunotherapy","indication":"Colorectal cancer","status":"phase_2"},{"name":"Dronabinol in Oral Dosage Form","genericName":"Dronabinol in Oral Dosage Form","slug":"dronabinol-in-oral-dosage-form","indication":"Cancer-related anorexia and cachexia (Phase 3 investigation)","status":"phase_3"},{"name":"Vincristin","genericName":"Vincristin","slug":"vincristin","indication":"Acute lymphoid leukemia","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo in Oral Dosage Form","genericName":"Placebo in Oral Dosage Form","slug":"placebo-in-oral-dosage-form","indication":"Clinical trial control arm (indication depends on the active comparator drug being studied)","status":"phase_3"}]}],"pipeline":[{"name":"Cetuximab Induction","genericName":"Cetuximab Induction","slug":"cetuximab-induction","phase":"phase_2","mechanism":"Cetuximab is a monoclonal antibody that targets and binds to the epidermal growth factor receptor (EGFR), preventing its activation and subsequent signaling.","indications":["Colorectal cancer","Head and neck cancer"],"catalyst":""},{"name":"Cetuximab Radioimmunotherapy","genericName":"Cetuximab Radioimmunotherapy","slug":"cetuximab-radioimmunotherapy","phase":"phase_2","mechanism":"Cetuximab Radioimmunotherapy targets and destroys cancer cells by binding to the epidermal growth factor receptor (EGFR) and delivering a radioactive payload.","indications":["Colorectal cancer","Head and neck cancer"],"catalyst":""},{"name":"Dronabinol in Oral Dosage Form","genericName":"Dronabinol in Oral Dosage Form","slug":"dronabinol-in-oral-dosage-form","phase":"phase_3","mechanism":"Dronabinol is a synthetic cannabinoid that acts as a partial agonist at cannabinoid receptors CB1 and CB2, modulating endocannabinoid signaling to produce therapeutic effects.","indications":["Cancer-related anorexia and cachexia (Phase 3 investigation)","Chemotherapy-induced nausea and vomiting (potential indication)"],"catalyst":""},{"name":"Placebo in Oral Dosage Form","genericName":"Placebo in Oral Dosage Form","slug":"placebo-in-oral-dosage-form","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.","indications":["Clinical trial control arm (indication depends on the active comparator drug being studied)"],"catalyst":""},{"name":"Vincristin","genericName":"Vincristin","slug":"vincristin","phase":"marketed","mechanism":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","indications":["Acute lymphoid leukemia","Burkitt's lymphoma","Diffuse non-Hodgkin's lymphoma, large cell","Follicular non-Hodgkin's lymphoma","Hodgkin's disease"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":2,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}